Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

HERCULES CAPITAL, INC.

(HTGC)
  Report
Delayed Nyse  -  04:00 2022-09-30 pm EDT
11.58 USD   +1.14%
09/13Hercules Receives a BBB+ Reaffirmed Investment Grade Corporate Rating from Kroll Bond Rating Agency, Inc.
BU
09/01Sector Update: Health Care Stocks Slip Pre-Bell Thursday
MT
09/01Provention Bio Secures $125 Million Term Loan Facility With Hercules Capital
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nyse
09/26/2022 09/27/2022 09/28/2022 09/29/2022 09/30/2022 Date
11.9(c) 12.04(c) 12.38(c) 11.45(c) 11.58(c) Last
3 029 187 1 525 144 989 888 1 603 307 1 348 521 Volume
-7.03% +1.18% +2.82% -7.51% +1.14% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 302 M - -
Net income 2022 80,7 M - -
Net Debt 2022 - - -
P/E ratio 2022 18,3x
Yield 2022 14,1%
Sales 2023 352 M - -
Net income 2023 200 M - -
Net Debt 2023 - - -
P/E ratio 2023 7,52x
Yield 2023 12,2%
Capitalization 1 460 M 1 460 M -
Capi. / Sales 2022 4,84x
Capi. / Sales 2023 4,15x
Nbr of Employees -
Free-Float 97,5%
More Financials
Company
Hercules Capital, Inc. is a specialty finance company. It is focused on providing senior secured loans to venture capital-backed and institutional-backed companies in a variety of technology, life sciences and sustainable and renewable technology industries. The Company is an internally managed, non-diversified, closed-end investment company. Its investment objective is to maximize its portfolio total return by... 
More about the company
Ratings of Hercules Capital, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about HERCULES CAPITAL, INC.
09/13Hercules Receives a BBB+ Reaffirmed Investment Grade Corporate Rating from Kroll Bond R..
BU
09/01Sector Update: Health Care Stocks Slip Pre-Bell Thursday
MT
09/01Provention Bio Secures $125 Million Term Loan Facility With Hercules Capital
MT
08/31Provention Bio Announces $125 Million Term Loan Facility with Hercules Capital
PR
08/30Hercules Capital to Provide Alladapt Immunotherapeutics With Term Loan of Up to $50 Mil..
MT
08/30Alladapt Announces Loan Agreement with Hercules Capital
AQ
08/30Alladapt Immunotherapeutics, Inc. announced that it expects to receive $50 million in f..
CI
08/15Atai Life Sciences Reports Term Loan Facility of Nearly $175 Million
MT
08/15Atai Life Sciences Secures Term Loan Facility for up to $175 Million from Hercules Capi..
AQ
08/08HERCULES CAPITAL, INC. : Ex-dividend day for
FA
08/04Amgen Inc. (NasdaqGS:AMGN) entered into a definitive agreement to a..
CI
08/02Phathom Pharmaceuticals Reports Wider Loss in Q2; Shares Tumble 29%
MT
08/01JMP Securities Adjusts Hercules Capital's Price Target to $18 from $19, Keeps Market Ou..
MT
08/01North American Morning Briefing:Stock Futures -2-
DJ
07/29Oppenheimer Downgrades Hercules Capital to Perform From Outperform, Adjusts Price Targe..
MT
More news
News in other languages on HERCULES CAPITAL, INC.
09/01Mise à jour sectorielle : Les actions du secteur de la santé gli..
09/01Provention Bio obtient une facilité de prêt à terme de 125 millions de dollars avec Her..
08/15Atai Life Sciences annonce une facilité de prêt à terme de près de 175 millions de doll..
08/02Phathom Pharmaceuticals annonce une perte plus importante au deuxième trimestre ; les a..
07/29Les revenus nets de placement par action de Hercules Capital restent stables au deuxièm..
More news
Analyst Recommendations on HERCULES CAPITAL, INC.
More recommendations
ETFs positioned on HERCULES CAPITAL, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
VanEck Vectors BDC Income ETF - USD4.45%-5.57%United_States
Virtus Private Credit Strategy ETF - USD2.2%-3.32%-NC
IShares Listed Private Equity (Acc) - USD1.41%-1.89%-World
IShares Listed Private Equity (Dist) - USD1.41%-5.93%World
Invesco Global Listed Private Equity ETF - USD0.55%-1.40%World
More ETFs positioned on HERCULES CAPITAL, INC.
Chart HERCULES CAPITAL, INC.
Duration : Period :
Hercules Capital, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HERCULES CAPITAL, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 11,58 $
Average target price 16,75 $
Spread / Average Target 44,6%
EPS Revisions
Managers and Directors
Scott Bluestein President, Chief Executive Officer & Director
Seth H. Meyer Chief Financial & Accounting Officer
Robert P. Badavas Chairman
Steve Kuo Senior Managing Director & Group Head-Technology
Christian Follmann Chief Operating Officer